Table 1

Patent information on selected NCATS molecules.

Molecule codePatent no.Patent namePriority date*InventorsNotes
LY500303077,354,951Substituted benzopyrans as selective estrogen receptor–β agonists5 October 2005Bryan Hurst Norman; Timothy Ivo Richardson
7,442,812Substituted benzopyrans as selective estrogen receptor–β agonists8 April 2004Gregory Lee Durst; Bryan Hurst Norman; Timothy Ivo Richarson
7,585,985Substituted benzopyrans as selective estrogen receptor–β agonists8 April 2004Bryan Hurst Norman; Lance Allen Pfeifer; Timothy Ivo RichardsonDivisional of ‘812 patent†
7,842,822Substituted benzopyrans as selective estrogen receptor–β agonists8 April 2004Gregory Lee Durst; Bryan Hurst Norman; Timothy Ivo RichardsonDivisional of ‘812 patent†
AZF0530(2 projects)8,304,417Crystalline forms of 4-(6-chloro-2, 3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl) ethoxy]-5-tetrahydropyran-4-yloxyquinazoline14 December 2005James Gair Ford et al.
ZD40545,866,568Heterocyclic compounds4 June 1996Robert Hugh Bradbury et al.
6,060,475Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof4 June 1996Robert Hugh Bradbury et al.Divisional of ‘568 patent†
6,258,817Substituted pyrazin-2-yl-sulphonamide (-3-pyridyl) compounds and uses thereof4 June 1996Robert Hugh Bradbury et al.Divisional of ‘568 patent†
PF-034632758,124,639Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors6 April 2006Stanton F. McHardy; John A. Lowe III

*The priority date is the date from which the 20-year patent term begins. †A divisional is a patent that is a subset of, and thus has the same priority date as, a prior patent.